170 related articles for article (PubMed ID: 16151771)
21. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts.
Vaidyanathan G; Friedman HS; Affleck DJ; Schottelius M; Wester HJ; Zalutsky MR
Clin Cancer Res; 2003 May; 9(5):1868-76. PubMed ID: 12738745
[TBL] [Abstract][Full Text] [Related]
22. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
[TBL] [Abstract][Full Text] [Related]
23. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.
Decristoforo C; Mather SJ; Cholewinski W; Donnemiller E; Riccabona G; Moncayo R
Eur J Nucl Med; 2000 Sep; 27(9):1318-25. PubMed ID: 11007513
[TBL] [Abstract][Full Text] [Related]
24. Dosimetric measurements of (68)Ga-high affinity DOTATATE: twins in spirit - part III.
Hartmann H; Freudenberg R; Oehme L; Zöphel K; Schottelius M; Wester HJ; Wunderlich G; Kotzerke J; Brogsitter C
Nuklearmedizin; 2014; 53(5):211-6. PubMed ID: 25029274
[TBL] [Abstract][Full Text] [Related]
25. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates.
Schottelius M; Wester HJ; Reubi JC; Senekowitsch-Schmidtke R; Schwaiger M
Bioconjug Chem; 2002; 13(5):1021-30. PubMed ID: 12236784
[TBL] [Abstract][Full Text] [Related]
26. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
Kaltsas GA; Mukherjee JJ; Grossman AB
Ann Oncol; 2001; 12 Suppl 2():S47-50. PubMed ID: 11762352
[TBL] [Abstract][Full Text] [Related]
27. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR
Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500
[TBL] [Abstract][Full Text] [Related]
28. Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide.
Boubaker A; Prior JO; Willi JP; Champendal M; Kosinski M; Bischof Delaloye A; Maecke HR; Ginj M; Baechler S; Buchegger F
Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1868-75. PubMed ID: 22940856
[TBL] [Abstract][Full Text] [Related]
29. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
[TBL] [Abstract][Full Text] [Related]
30. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP
Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
[TBL] [Abstract][Full Text] [Related]
32. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study.
Decristoforo C; Maina T; Nock B; Gabriel M; Cordopatis P; Moncayo R
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1211-9. PubMed ID: 12845487
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC
Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
[TBL] [Abstract][Full Text] [Related]
34. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
[TBL] [Abstract][Full Text] [Related]
35. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM
Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146
[TBL] [Abstract][Full Text] [Related]
36. 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours.
Hashemi SH; Benjegård SA; Ahlman H; Wängberg B; Forssell-Aronsson E; Billig H; Nilsson O
Br J Surg; 2003 May; 90(5):549-54. PubMed ID: 12734860
[TBL] [Abstract][Full Text] [Related]
37. [111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.
Bakker WH; Albert R; Bruns C; Breeman WA; Hofland LJ; Marbach P; Pless J; Pralet D; Stolz B; Koper JW
Life Sci; 1991; 49(22):1583-91. PubMed ID: 1658515
[TBL] [Abstract][Full Text] [Related]
38. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.
Rodrigues M; Traub-Weidinger T; Li S; Ibi B; Virgolini I
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):532-40. PubMed ID: 16491425
[TBL] [Abstract][Full Text] [Related]
40. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
